The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Adults with Primary Insomnia
Open accessAbstract
STUDY OBJECTIVES: To evaluate the efficacy and safety of doxepin 1, 3, and 6 mg in insomnia patients. DESIGN: Adults (18-64 y) with chronic primary insomnia (DSM-IV) were randomly assigned to one of four sequences of 1 mg, 3 mg, and 6 mg of doxepin, and placebo in a crossover study. Treatment periods consisted of 2 polysomnographic assessment nights with a 5-day or 12-day drug-free interval between periods. Efficacy was assessed using polysomnography (PSG) and patient-reported measures. Safety analyses included measures of residual sedation and adverse events. MEASUREMENTS AND RESULTS: Sixty-seven patients were randomized. Wake time during sleep, the a priori defined primary endpoint, was statistically significantly improved at the doxepin 3 mg and 6 mg doses versus placebo. All three doses had statistically significant improvements versus placebo for PSG-defined wake after sleep onset, total sleep time, and overall sleep efficiency (SE). SE in the final third-of-the-night also demonstrated statistically significant improvement at all doses. The doxepin 6 mg dose significantly reduced subjective latency to sleep onset. All three doxepin doses had a safety profile comparable to placebo. There were no statistically significant differences in next-day residual sedation, and sleep architecture was generally clinically preserved. CONCLUSIONS: In adults with primary insomnia, doxepin 1 mg, 3 mg, and 6 mg was well-tolerated and produced improvement in objective and subjective sleep maintenance and duration endpoints that persisted into the final hour of the night. The side-effect profile was comparable to placebo, with no reported anticholinergic effects, no memory impairment, and no significant hangover/next-day residual effects. These data demonstrate that doxepin 1 mg, 3 mg, and 6 mg is efficacious in improving the sleep of patients with chronic primary insomnia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young Adults
Breslau, N., Roth, T., Rosenthal, L., & Andreski, P. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00188-3 · Cited by 1,831
Self-citationSedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005) · BMJ · doi:10.1136/bmj.38623.768588.47 · Cited by 1,161 · cited 1×
“(4) intentionally napping >2 times/week; (5) having a variation in bedtime >2 hours on 5 of 7 nights, based on screening sleep diaries; (5) having a history of cognitive disorders, depression, schizophrenia, panic disorder, dementia, chronic pain, glaucoma, or frequent nightly urination (>2 times per night); (6) havin…”
BackgroundInternational Union of Pharmacology. XIII. Classification of Histamine Receptors
Hill, S. J., Ganellin, C. R., Timmerman, H., Schwartz, J. C., Shankley, N. P., Young, J. M., Schunack, W., Levi, R., & Haas, H. L. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01328-0 · Cited by 899
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Edgar, D., Dement, W., & Fuller, C. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-03-01065.1993 · Cited by 666
Clinical correlates of insomnia in patients with chronic illness
Katz, D. A., & McHorney, C. A. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.10.1099 · Cited by 480 · cited 1×
“(4) intentionally napping >2 times/week; (5) having a variation in bedtime >2 hours on 5 of 7 nights, based on screening sleep diaries; (5) having a history of cognitive disorders, depression, schizophrenia, panic disorder, dementia, chronic pain, glaucoma, or frequent nightly urination (>2 times per night); (6) havin…”
BackgroundOhayon, M. M. (1997) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00002-2 · Cited by 423
Hajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00491.x · Cited by 404
Impaired locomotor activity and exploratory behavior in mice lacking histamine H 1 receptors
Inoue, I., Yanai, K., Kitamura, D., Taniuchi, I., Kobayashi, T., Niimura, K., Watanabe, T., & Watanabe, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13316 · Cited by 298
Residual Effects of Hypnotics: Epidemiology and Clinical Implications
Vermeeren, A. (2004) · CNS Drugs · doi:10.2165/00023210-200418050-00003 · Cited by 277
Cited by
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Morin, C. M., & Benca, R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60750-2 · Cited by 976
Sleep, insomnia, and depression
Riemann, D., Krone, L. B., Wulff, K., & Nissen, C. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0411-y · Cited by 819
Wilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Metadata
- Authors
- Roth, T., Rogowski, R., Hull, S., Schwartz, H., Koshorek, G., Corser, B., Seiden, D., & Lankford, A.
- Venue
- Sleep
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11
- Volume
- 30
- Issue
- 11
- Pages
- 1555-1561
- ISSN
- 0161-8105 (ISSN-L)
- 1550-9109
- OpenAlex
- W15424833
- Cited by
- 338
- References
- 26
- FWCI
- 15.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Adults with Primary Insomnia. https://app.cochat.ai/papers/10.1093/sleep/30.11.1555
- The paper
- Roth, T., Rogowski, R., Hull, S., Schwartz, H., Koshorek, G., Corser, B., Seiden, D., & Lankford, A. (2007). Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Adults with Primary Insomnia. Sleep. https://doi.org/10.1093/sleep/30.11.1555
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.